PBYI vs YDES
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PBYI presents a stable Piotroski F-Score of 4/9, but the stock is currently trading at a significant premium to its Graham Number ($5.96) and Intrinsic Value ($4.27). While the company maintains impressive gross margins (74.53%) and a strong ROE (27.97%), these are offset by a concerning -34.4% YoY earnings growth. With a technical trend score of 10/100 and an analyst target price of $5.00, the current price of $7.24 appears fundamentally overextended. Bearish insider activity from the CEO and CFO further suggests a lack of confidence in near-term upside.
YDES exhibits severe financial instability characterized by a weak Piotroski F-Score of 3/9 and a catastrophic technical trend. While the company maintains a pristine balance sheet with zero debt and an exceptional current ratio of 13.18, these are offset by an absurd Price-to-Sales ratio of 724.75 and deeply negative operating margins (-444.59%). The stock is currently in a freefall, trading near its 52-week low after a 60.7% one-year decline, suggesting a massive loss of investor confidence despite high year-over-year revenue growth.
Compare Another Pair
Related Comparisons
PBYI vs YDES: Head-to-Head Comparison
This page compares Puma Biotechnology, Inc. (PBYI) and YD Bio Ltd (YDES) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.